Your session is about to expire
← Back to Search
Bupivacaine Arm for Postoperative Pain
N/A
Waitlist Available
Led By Carson T Kaeser, MD
Research Sponsored by The Christ Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Any woman over the age of 18 years with a capacity to give informed consent who are undergoing vaginal prolapse surgery including a posterior colporrhaphy may be included in the study.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
To determine if levator muscle block with bupivacaine improves postoperative pain control relative to placebo controls among women undergoing prolapse surgery involving a posterior colporrhaphy. Improvement is defined as no less than a 25% lower total pain score on a ten point numerical pain scale.
Eligible Conditions
- Postoperative Pain
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients with improvement in pain, scored on a 10 point numerical pain scale.
Secondary outcome measures
Length of hospital stay measured in hours.
Measure of morphine equivalents used in patients postoperatively.
Postoperative care satisfaction scores, graded with a post-operative survey.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Bupivacaine ArmActive Control1 Intervention
The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
Group II: Placebo ArmPlacebo Group1 Intervention
The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
Find a Location
Who is running the clinical trial?
The Christ HospitalLead Sponsor
19 Previous Clinical Trials
1,265 Total Patients Enrolled
The University of Kansas Medical CenterUNKNOWN
1 Previous Clinical Trials
457 Total Patients Enrolled
Carson T Kaeser, MDPrincipal InvestigatorThe Christ Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger